New Version,Nov. 8, 2023

The question of when was tirzepatide approved has become increasingly relevant as this medication has expanded its indications and reached a wider patient population. While the drug has seen significant developments in recent years, its approval timeline is multifaceted, reflecting its initial use and subsequent expansions.

Tirzepatide, known by its brand names Mounjaro and Zepbound, is a dual-acting GIP and GLP-1 receptor agonist developed by Eli Lilly and Company. Understanding its approval history requires looking at its initial authorization for type 2 diabetes and its later approval for chronic weight management.

The Initial Approval: Tirzepatide for Type 2 Diabetes

The journey of tirzepatide began with its approval for improving glycemic control in adults with type 2 diabetes. The U.S. Food and Drug Administration (FDA) granted its first approval for this indication on May 13, 2022. On this date, the drug was authorized under the brand name Mounjaro as an adjunct to diet and exercise. This marked a significant moment, as Mounjaro (tirzepatide) was the first in a new class of medications targeting both GIP and GLP-1 receptors.

This initial approval in the United States was a crucial step. Following this, tirzepatide also received approval in the European Union in September 2022 for the treatment of type 2 diabetes. The Mounjaro FDA approval history clearly indicates this pivotal date for diabetes management.

Expansion to Chronic Weight Management

The efficacy of tirzepatide in promoting weight loss became evident, leading to further research and regulatory review. The FDA recently approved tirzepatide for chronic weight management. This significant expansion occurred on November 8, 2023, when the FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight, along with at least one weight-related condition. This approval was granted for individuals with a BMI of 27 kg/m² or greater.

This approval on Wednesday approved Eli Lilly's blockbuster drug tirzepatide for weight loss paved the way for its wider use beyond diabetes management. The FDA approves Zepbound (tirzepatide) signifies a new era for weight management therapies. It's important to note that tirzepatide is already approved to treat type 2 diabetes, and this new indication broadens its therapeutic scope.

Further Approvals and Future Indications

The regulatory landscape for tirzepatide continues to evolve. While the initial approvals focused on diabetes and weight management, research has explored its potential for other conditions. For instance, there are indications of FDA approval for obstructive sleep apnea (OSA), with some sources suggesting this occurred in December 2024. The FDA approves Zepbound (tirzepatide) for moderate to severe OSA in adults with obesity, marking it as the first and only prescription medicine for this condition. This highlights the versatility of tirzepatide.

The Mounjaro (tirzepatide) FDA approval history and the Zepbound FDA approval history demonstrate a strategic and phased approach by Eli Lilly and Company to bring this innovative medication to patients for various health needs. The drug has been FDA Approved: Yes for both its primary indications. The timeline shows May 13, 2022, as the initial approval date for Mounjaro, and November 8, 2023, for Zepbound. These dates are crucial for understanding the tirzepatide FDA approval journey.

In summary, while tirzepatide was first approved in May 2022 for type 2 diabetes, its journey continued with further approvals, including its significant authorization for chronic weight management on November 8, 2023. The ongoing development and potential for new indications underscore the importance of staying informed about the latest updates regarding this groundbreaking medication.